证券代码：301117 证券简称：佳缘科技 佳缘科技股份有限公司投资者关系活动记录表 编号：2022-011 | --- | --- | --- | |-----------------------------|--------------------------------------------------|--------------------------------------------| | | | | | | ☑ 特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | | | | 华泰证券：李聪 | | | | 华安基金：花超 | | | 参与单位名称及人员 | 申万菱信：诸天力 | | | 姓名 | 南方基金：邹承原 | | | | 华富基金：范亮 | | | | 先进制造业基金：尹高杨 | | | 时间 | 2022 年 6 月 5 日 | | | 地点 | 通过电话会议线上交流 | | | | 董事长、总经理：王进 | | | 上市公司接待人员姓 | 董事、 ...

证券代码：301117 证券简称：佳缘科技 佳缘科技股份有限公司投资者关系活动记录表 编号：2022-017 | --- | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------| | | | | | | | ☑ 特定对象调研 | □分析师会议 | | | | □媒体采访 | □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | □其他 | | | | 参与单位名称及人员 姓名 | 源乐晟：梁皓、董昊 中金资管：董俊业、周文菁 千合资本：邵珠印 | | | | | 中再资产：孙博睿 人保资产：李金阳 | | | | 时间 ...

证券代码：301117 证券简称：佳缘科技 佳缘科技股份有限公司投资者关系活动记录表 编号：2022-019 | --- | --- | --- | |-----------------------------|------------------------------------------------------------------------------------------------------------------|-------| | | | | | | 特定对象调研 □分析师会议 | | | 投资者关系活动类别 | □业绩说明会 | | | | □路演活动 | | | | | | | | | | | | 易方达基金：何一铖 | | | | 创金合信：郭镇岳、王妍、谢天卉、陈建军、刘扬 建信保险：孔硕 | | | 参与单位名称及人员 姓名 | 浦银安盛基金：朱盛按 东方财富：卢嘉鹏 | | | | 财通证券：杨烨 | | | | 民生证券：吕伟、赵奕豪 | | | 时间 | 11 日 | | | 地点 | 佳缘科技股份有限公司会议室（成都） | | | 上市公司接待人员 | 副总经理兼 ...

证券代码：301117 证券简称：佳缘科技 编号：2022-016 | --- | --- | --- | |-------------------------|--------------------------------------------------------------------------------------------------------------------------|----------| | | | | | | 特定对象调研 □分析师会议 | | | 投资者关系活动类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | | | | 参与单位名称及人员 姓名 | 华商证券：吴昊、陈恒、刘力 中信证券：潘儒琛、朱珏琦 | | | | | | | 时间 | 月 7 日 佳缘科技股份有限公司北京分公司（北京市海淀区建 | | | 地点 上市公司接待人员姓 | 27 号中关村科学城金隅智造 1 董事长、总经理：王进 | 栋 203） | | 名 投资者关系活动主要 | 一、告知保密义务： 签署保密承诺书 二、公司基 ...

证券代码：301117 证券简称：佳缘科技 佳缘科技股份有限公司投资者关系活动记录表 编号：2022-015 | --- | --- | --- | |--------------------|--------------------------------|--------------| | | | | | | □特定对象调研 | ☑ 分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | | | | 天风证券：李鲁靖、刘明洋 | | | | 广发 证券 ：杨志栋 | | | | 国金证券：边广洁 | | | | 禅龙资产：杨博显 | | | | 上海保银：邹舟 | | | | 百年保险：李兴宇 | | | | 银河证券：石磊 | | | 参与单位名称及人员 | 上海冲积中心（有限合伙）：桑梓 | | | 姓名 | 百年保险：许娟娟 | | | | 华安证券： 饶晓鹏、花超 | | | | 江信基金：杨凡 | | | | 浦银安盛：李浩玄 | | | | 长安证券：刘嘉 | | | | 中欧基金： ...

证券代码：301117 证券简称：佳缘科技 佳缘科技股份有限公司投资者关系活动记录表 编号：2022-018 | --- | --- | |--------------------|----------------------------------------| | | | | | 特定对象调研 □分析师会议 | | | □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | | | | | | 东方阿尔法基金：刘明、高丰臣、曹永毅 | | | | | | 合众易晟投资：唐紫阳 | | | 广发证券成都分公司：胡哲伟、张湘、龚宁 | | | | | | 中金资管：朱剑胜、刘刚 | | | | | 参与单位名称及人员 | | | 姓名 | | | | 成都翰聚资产：杜光平 | | | | | | 广发证券：孟祥杰、曹一凡 | | | 中大君悦投资：吴季轩、曲芳 | | | | | | 成都聚翰资产：陆宁 | | | 西藏隆源投资：喻磊 | | --- | --- | |-----------------------------------|------------------- ...

Financial Performance - The company's revenue for Q3 2022 was ¥13,162,205.80, a decrease of 44.21% compared to the same period last year[6]. - The net profit attributable to shareholders was -¥6,095,743.25, reflecting a decline of 213.90% year-on-year[6]. - The basic and diluted earnings per share were both -¥0.07, down 190.50% from the previous year[6]. - Total revenue for Q3 2022 was CNY 161,597,417.88, an increase from CNY 156,841,606.50 in the same period last year, representing a growth of approximately 2.4%[22]. - Net profit for Q3 2022 was CNY 36,327,036.14, compared to CNY 44,681,348.56 in Q3 2021, reflecting a decrease of approximately 18.7%[23]. - Total comprehensive income for Q3 2022 was CNY 36,327,036.14, compared to CNY 44,681,348.56 in Q3 2021, representing a decrease of approximately 18.5%[24]. - Basic and diluted earnings per share for Q3 2022 were both CNY 0.41, down from CNY 0.65 in the same period last year, indicating a decline of 36.9%[24]. - The company reported an operating profit of CNY 38,914,155.61 for Q3 2022, down from CNY 49,960,581.11 in the previous year, a decline of approximately 22.1%[23]. Assets and Liabilities - Total assets increased to ¥1,356,326,519.84, representing a growth of 193.01% compared to the end of the previous year[6]. - Total assets as of September 30, 2022, reached CNY 1,356,326,519.84, compared to CNY 462,895,838.51 at the start of the year, indicating a growth of about 194.5%[20]. - Total liabilities decreased to CNY 64,890,341.16 from CNY 165,874,216.12, a reduction of approximately 60.9%[20]. - The company's equity attributable to shareholders rose to ¥1,290,124,372.07, an increase of 336.72% year-on-year[6]. - The company's equity attributable to shareholders increased to CNY 1,290,124,372.07 from CNY 295,411,448.02, reflecting a growth of about 336.5%[20]. Cash Flow - Cash flow from operating activities showed a net outflow of -¥171,605,633.62 for the year-to-date, a decline of 182.13%[6]. - Cash inflow from operating activities totaled CNY 123,713,711.96, an increase of 7.3% from CNY 115,449,495.65 in Q3 2021[25]. - Net cash outflow from operating activities was CNY -171,605,633.62, worsening from CNY -60,824,672.44 in the previous year[26]. - Cash flow from investing activities resulted in a net outflow of CNY -12,518,306.50, compared to CNY -2,609,790.92 in Q3 2021[26]. - Cash flow from financing activities generated a net inflow of CNY 872,152,703.60, significantly higher than CNY 6,152,486.32 in the same period last year[26]. - The ending balance of cash and cash equivalents was CNY 749,973,152.38, up from CNY 23,418,621.66 at the end of Q3 2021[26]. - The company reported a significant increase in cash received from investment activities, totaling CNY 1,860,000,000.00[26]. - Total cash outflow for operating activities was CNY 295,319,345.58, compared to CNY 176,274,168.09 in Q3 2021, reflecting a rise of 67.4%[26]. Research and Development - Research and development expenses for the first nine months of 2022 were ¥33,993,283.25, an increase of 86.67% compared to the same period in 2021[10]. - Research and development expenses for Q3 2022 amounted to CNY 33,993,283.25, significantly higher than CNY 18,210,314.72 in the previous year, marking an increase of about 86.5%[23]. - The company plans to continue expanding its research and development efforts and increase its market presence through strategic initiatives[10]. - The company has a strategic focus on enhancing its technological capabilities through ongoing research and development initiatives[16]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 5,744[13]. - The largest shareholder, Wang Jin, holds 37.68% of the shares, amounting to 34,765,500 shares[13]. - The top ten shareholders collectively hold significant stakes, with the top three individuals holding a combined 54.75% of the shares[13]. - The company has a total of 72,346,991 restricted shares, with 1,085,476 shares released from restriction on July 18, 2022, representing 1.1765% of the total shares post-IPO[17]. - The total number of shares held by the top ten unrestricted shareholders includes significant institutional investments, indicating strong market confidence[14]. - The next release of restricted shares for major shareholders is scheduled for January 2023, which may impact share liquidity[15]. Future Outlook - The company plans to maintain its focus on market expansion and new product development in the upcoming quarters[16]. - The company’s future outlook remains positive, with expectations for continued growth in user data and market share[16]. - The company has not disclosed any new mergers or acquisitions during this reporting period[16]. Audit Status - The report for Q3 2022 was not audited[28].

Financial Performance - The company reported a revenue of 500 million RMB for the first half of 2022, representing a year-on-year increase of 20%[18]. - The company has set a revenue target of 1.2 billion RMB for the full year 2022, indicating a growth forecast of 25% compared to 2021[18]. - The company's operating revenue for the reporting period was CNY 148,435,212.08, representing an increase of 11.40% compared to the same period last year[28]. - The net profit attributable to shareholders was CNY 42,721,147.15, reflecting a growth of 7.10% year-over-year[28]. - The net profit after deducting non-recurring gains and losses decreased by 11.78% to CNY 34,156,405.71 compared to the previous year[28]. - The net cash flow from operating activities was negative at CNY -137,752,812.40, a decline of 371.52% from the previous year[28]. - Total assets increased by 200.90% to CNY 1,392,843,473.54 compared to the end of the previous year[28]. - The net assets attributable to shareholders rose by 338.78% to CNY 1,296,220,115.32 compared to the end of the previous year[28]. - The company achieved total revenue of 148.44 million yuan, an increase of 11.40% compared to the same period last year[38]. - The company reported government subsidies amounting to CNY 2,581,908.25, contributing to its financial performance[32]. User Growth and Market Expansion - User data showed an increase in active users by 15%, reaching a total of 1.2 million users by June 30, 2022[18]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[18]. - The company reported a significant increase in user data, with a growth rate of 25% year-over-year in active users[104]. - User data showed a growth of 15% in active users, reaching 10 million by the end of June 2022[106]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[104]. Research and Development - The company is investing 50 million RMB in R&D for new technologies in the healthcare sector[18]. - The company's R&D investment increased by 27.48% to ¥15,707,793.66, up from ¥12,321,679.15 in the previous year, reflecting a commitment to technology innovation[63]. - The company established a new R&D center in Shanghai, focusing on satellite data security and automation detection equipment, among other projects[54]. - The company has developed two core technologies in the field of wireless data security transmission, including a satellite data protection technology and a parallel processing method for transactional databases[55]. - The company has authorized 9 patents and has 18 patents under review, along with 120 software copyrights, indicating a strong focus on intellectual property development[58]. - Research and development expenses increased by 30% to 300 million CNY, focusing on innovative technologies and product enhancements[108]. - The company is focusing on enhancing its technological capabilities through ongoing research and development initiatives[192]. Strategic Initiatives - New product development includes the launch of a next-generation security platform, expected to enhance market competitiveness[18]. - A strategic acquisition of a local tech firm is in progress, aimed at enhancing technological capabilities and service offerings[18]. - A strategic acquisition is in progress, aimed at bolstering the company's technological capabilities and product offerings[104]. - The company has established a wholly-owned subsidiary to focus on radar and related equipment R&D, which will support its sustainable development capabilities[54]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[196]. Risk Management - The management highlighted potential risks including market competition and regulatory changes, with strategies in place to mitigate these risks[4]. - The company faces risks related to research and development, particularly in keeping pace with rapid technological changes and customer demands in the information technology sector[100]. - The ongoing COVID-19 pandemic poses uncertainties that could impact the company's operations and financial performance, particularly due to potential reductions in government spending[102]. - The company aims to mitigate order fluctuation risks by expanding its user base and scale, as market competition intensifies in the information security industry[102]. - The company has implemented measures to enhance talent management and reduce personnel turnover risks, including performance assessments and incentive systems[101]. Corporate Governance and Compliance - The company will not distribute cash dividends or issue bonus shares for the reporting period[5]. - There were no changes in the board of directors, supervisors, or senior management during the reporting period[111]. - The company has not engaged in any major related party transactions during the reporting period[128]. - The half-year financial report has not been audited[125]. - The company has not reported any share repurchase progress in the current period[150]. Financial Position and Cash Flow - The total liabilities decreased to ¥95,168,533.24 from ¥165,874,216.12, a reduction of 42.5%[172]. - Shareholders' equity increased to ¥1,297,674,940.30 from ¥297,021,622.39, reflecting a growth of 336.5%[172]. - The company reported a net cash flow from operating activities of -137,752,812.40 yuan for the first half of 2022, compared to -29,214,812.25 yuan in the same period of 2021, indicating a significant decline in operational cash flow[184]. - The total cash and cash equivalents increased by 745,520,203.79 yuan, ending the period with a balance of 807,464,592.69 yuan, compared to 46,071,710.72 yuan at the end of the previous year[186]. - The company reported cash inflow from other investment activities of 1,340,000,000.00 yuan, which contributed significantly to the overall cash position[186].

Financial Performance - The company's operating revenue for Q1 2022 was ¥14,337,503.35, representing a 358.64% increase compared to ¥3,126,105.77 in the same period last year[3] - The net profit attributable to shareholders was a loss of ¥4,301,233.00, an improvement of 35.99% from a loss of ¥6,719,941.03 in the previous year[3] - The company's total revenue for the current period was RMB 14.34 million, compared to RMB 3.13 million in the previous period, reflecting an increase of approximately 358.0%[22] - The net profit for the first quarter of 2022 was -4,475,022.69 CNY, compared to -6,871,669.89 CNY in the previous year, showing an improvement of about 34.8%[24] - The operating profit for the first quarter was -3,965,251.31 CNY, which is an improvement from -6,635,485.34 CNY year-over-year[26] - The company reported a total comprehensive loss of -4,475,022.69 CNY for the quarter, compared to -6,871,669.89 CNY in the previous year, indicating a reduction in losses[24] Cash Flow and Assets - The net cash flow from operating activities was -¥51,217,896.08, which is a 24.72% decline compared to -¥41,066,923.70 in the same period last year[3] - The cash flow from operating activities was -51,217,896.08 CNY, worsening from -41,066,923.70 CNY in the previous year[26] - The cash flow from investing activities generated a net inflow of 2,009,470.27 CNY, compared to a net outflow of -313,828.97 CNY last year[27] - The cash flow from financing activities resulted in a net inflow of 977,580,015.87 CNY, a significant increase compared to -550,099.06 CNY in the previous year[27] - The company's cash and cash equivalents increased significantly to RMB 990.48 million from RMB 62.11 million at the beginning of the year, representing a growth of approximately 1498.5%[18] - Total current assets reached RMB 1,384.00 million, up from RMB 444.57 million at the beginning of the year, indicating a growth of approximately 211.5%[18] - The total liabilities decreased to RMB 112.77 million from RMB 165.87 million, a reduction of approximately 32.0%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,305[9] - Major shareholder Wang Jin holds 37.68% of the shares, amounting to 34,765,500 shares[10] - The top 10 shareholders collectively control 40.23% of the company's equity[10] - The total number of shares held by the top 10 unrestricted shareholders is 2,120,000[12] - The company has a total of 69,190,000 restricted shares at the beginning of the period, with 3,269,091 shares becoming unrestricted[13] - The company plans to release restricted shares for major shareholders on specific dates, with Wang Jin's shares set to be released on January 16, 2025[12] - The company has a significant presence of institutional investors, including several mutual funds holding shares[10] Research and Development - Research and development expenses rose by 54.27% to ¥8,589,768.87, reflecting the company's increased investment in R&D[7] - Research and development expenses increased to 8,589,768.87 CNY from 5,567,963.74 CNY, marking a rise of approximately 54.3%[26] - The company obtained two invention patents on March 22, 2022, enhancing its technological capabilities[16] Governance and Strategic Initiatives - The company completed the election of its third board of directors and supervisory board on February 22, 2022, ensuring governance stability[15] - The company has not reported any new product launches or technological advancements in this quarter[11] - There are no indications of market expansion or mergers and acquisitions in the current report[11] - The company has not disclosed any new strategic initiatives in the latest earnings call[11] Fundraising and Investment Plans - The company raised a total of RMB 1,079.83 million through the issuance of 23.0733 million shares at a price of RMB 46.80 per share, with a net amount of RMB 994.99 million after deducting issuance costs[14] - The registered capital increased from RMB 69.19 million to RMB 92.26 million following the issuance of new shares[15] - The company plans to invest the raised funds primarily in the upgrade of its information data platform and the construction of a research and testing center[14]

Financial Performance - The company reported a significant increase in user data, with a year-over-year growth of 25% in active users[16]. - The management highlighted a 30% increase in overall revenue for the fiscal year 2021, reaching 500 million RMB[16]. - The company's operating revenue for 2021 was ¥316,840,485.37, representing a 66.27% increase compared to ¥190,560,202.09 in 2020[19]. - The net profit attributable to shareholders for 2021 was ¥92,500,923.21, a 75.68% increase from ¥52,653,359.35 in 2020[19]. - The total assets at the end of 2021 reached ¥462,895,838.51, a 59.10% increase from ¥290,941,350.31 at the end of 2020[19]. - The net assets attributable to shareholders increased by 45.59% to ¥295,411,448.02 at the end of 2021 from ¥202,910,524.81 at the end of 2020[19]. - The basic earnings per share for 2021 was ¥1.34, a 76.32% increase compared to ¥0.76 in 2020[19]. - The weighted average return on equity for 2021 was 37.12%, up from 30.68% in 2020[19]. - The company achieved total operating revenue of CNY 316.84 million in 2021, a year-on-year increase of 66.27%[50]. - The net profit attributable to shareholders reached CNY 92.50 million, reflecting a growth of 75.68% compared to the previous year[50]. Future Outlook - Future outlook includes a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[16]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by 2025[16]. - The company is exploring potential mergers and acquisitions to enhance its service offerings and market reach, with a focus on tech startups[16]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 30% based on new product launches and market expansion strategies[185]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[185]. Research and Development - The company is investing in R&D for new technologies, with a budget allocation of 10 million RMB for the development of advanced security solutions[16]. - The company aims to enhance its information security product line, with a target of launching three new products in the next 12 months[16]. - Research and development expenses increased by 104.82% to ¥29.14 million, indicating a strong commitment to innovation[70]. - The R&D budget has been increased to 200 million yuan, emphasizing the commitment to innovation and technology advancement[185]. - The company has developed core technologies in high-performance distributed databases and data security protection, resulting in innovative products such as a medical data integration platform and a comprehensive command and dispatch platform[31]. Market Position and Strategy - The company is recognized as a leading enterprise in the information security field in Southwest China, focusing on continuous technological innovation and business expansion[29]. - The company focuses on providing network information security products and integrated information solutions primarily in the defense, healthcare, and government service sectors[36]. - The company is focused on expanding its product offerings, including automated reconciliation and unified gateway technologies, to enhance service delivery[56]. - The company aims to strengthen its market sales system and increase customer types and numbers, with plans to establish branches and R&D centers in Shanghai and Shijiazhuang in 2022[100]. - The company plans to enhance its customer service capabilities, investing 50 million yuan in training and technology upgrades[131]. Risk Management - The company has identified key risks in its operational strategy, including regulatory changes and market competition, which are discussed in detail in the management analysis section[5]. - The company faces risks related to R&D, including the need to keep pace with rapid technological changes and customer demands in the network information security sector[103]. - The company is addressing order fluctuation risks by expanding its user base and scale to mitigate the impact of changes in customer procurement policies[105]. - The COVID-19 pandemic has impacted the company's operations, with potential adverse effects on financial performance due to reduced government spending in relevant sectors[106]. Governance and Compliance - The company maintains a governance structure that ensures equal rights for all shareholders, particularly minority shareholders, and adheres to legal regulations[110]. - The board of directors consists of 5 members, including 2 independent directors, meeting the requirement of 1/3 independent representation[111]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with relevant laws[112]. - The company operates independently from its controlling shareholder in terms of assets, personnel, finance, and business, with no shared bank accounts or guarantees provided to the controlling shareholder[114][115]. - The company has established a comprehensive internal control system to effectively prevent operational risks and ensure compliance with laws and regulations[157]. Shareholder Returns - The company plans to distribute cash dividends of ¥4.00 per 10 shares, based on a total share base of 92,263,300 shares[151]. - The cash dividend amount for the reporting period is ¥36,905,320, which is 100% of the total profit distribution[151]. - The company adheres to a profit distribution policy that prioritizes cash dividends, with a minimum of 10% of distributable profits allocated for cash distribution each year[147]. - The company’s profit distribution plan is consistent with its articles of association and relevant regulations, ensuring transparency and protection of minority shareholders' rights[150]. - The company emphasizes a stable and sustainable profit distribution policy, aiming for a minimum cash dividend ratio of 80% during mature stages without significant capital expenditures[181]. Employee Management - The total number of employees at the end of the reporting period is 177, with 148 from the parent company and 29 from major subsidiaries[142]. - The total employee compensation for the reporting period amounts to ¥4,608,365.14, which represents 3.12% of the company's operating costs of ¥147,603,692.14[144]. - The company has established a comprehensive training system to enhance employee skills and knowledge, including a mentorship program for new employees[145]. - The company emphasizes a fair and competitive salary structure to attract and retain talent, aligning compensation with job responsibilities and performance[143]. Social Responsibility - The company actively participates in social responsibility initiatives, including providing advanced medical systems during the pandemic[167]. - The company emphasizes environmental protection and complies with relevant laws, reporting no violations during the reporting period[167]. - The company has made donations to charitable organizations, contributing to social welfare[176].